Evidence map›Paper›PMID 42212355›Full record

ReviewInternational journal of oncology2026

P2X7 receptor: An emerging therapeutic target in acute myeloid leukemia (Review).

Yunqing Liu, Hongfan Xue, Hanheng Mai, Tan Sang, Zonghong Li, Na Wang, Lili Feng

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in International journal of oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Yunqing LiuSchool of Clinical Medicine, Shandong Second Medical University, Weifang, Shandong 261053, P.R. China.
Hongfan XueOutpatient Department Management, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong 250117, P.R. China.
Hanheng MaiDepartment of Hematology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong 250117, P.R. China.
Tan SangDepartment of Hematology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong 250117, P.R. China.
Zonghong LiDepartment of Hematology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong 250117, P.R. China.
Na WangDepartment of Hematology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong 250021, P.R. China.
Lili FengDepartment of Hematology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong 250117, P.R. China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The P2X7 receptor (P2X7R) is a ligand‑gated ion channel that exhibits bifunctional properties, switching between a cation‑permeable channel and a large cytolytic pore. In acute myeloid leukemia (AML), P2X7R is aberrantly overexpressed, particularly in leukemia stem cells (LSCs) and AML blasts. Within the bone marrow niche of AML, P2X7R binding by extracellular adenosine triphosphate not only contributes to a profound immunosuppressive niche that protects the AML cells from immune surveillance, but also drives LSC proliferation, survival, homing, and self‑renewal through downstream signaling cascades, including the cAMP response element‑binding protein/phosphoglycerate dehydrogenase/serine metabolic axis, PBX homeobox 3, Wnt/β‑catenin, and c‑Myc. Elevated P2X7R expression is associated with poor prognosis, chemoresistance, and disease recurrence of AML. The central role of P2X7R in AML pathophysiology makes it a potential biomarker for prognostic stratification and a promising therapeutic target. Several targeting strategies are currently under investigation, including the small molecule antagonists and specific anti‑P2X7R antibodies. Furthermore, a therapeutic approach involves combining P2X7R inhibition with conventional chemotherapy. In conclusion, targeting the P2X7R pathway represents a potential novel and multi‑faceted strategy to improve outcomes for patients with AML by remodeling its protective microenvironment and directly attacking the leukemia cells.

Indexed as

Antineoplastic AgentsLeukemia, Myeloid, AcuteMolecular Targeted TherapyPurinergic P2X Receptor AntagonistsReceptors, Purinergic P2X7AnimalsHumansNeoplastic Stem CellsSignal TransductionTumor MicroenvironmentAntineoplastic AgentsP2RX7 protein, humanPurinergic P2X Receptor AntagonistsReceptors, Purinergic P2X7acute myeloid leukemiaimmune suppressionleukemic stem cellP2X7 receptortherapeutic target

Identifiers

PMID42212355
PMCPMC13238206

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.